Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection
Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection
复制标题
DOI：
10.1097/00007890-200010150-00011
复制
发表时间：
2000-10-15
期刊：
影响因子：
6.2
通讯作者：
Gebel, HM
中科院分区：
文献类型：
--
作者：
Tambur, AR;Bray, RA;Gebel, HM
Background. Historically, panel reactive antibody (PRA) analysis to detect HLA,antibodies has been performed using cell-based complement-dependent cytotoxicity (CDC) techniques. Recently, a flow cytometric procedure (FlowPRA) was introduced as an alternative approach to detect HLA antibodies, The flow methodology, using a solid phase matrix to which soluble HLA class I or class II antigens are attached is significantly more sensitive than CDC assays, How ever, the clinical relevance of antibodies detected exclusively by FlowPRAhas not been established. In this study of cardiac allograft recipients, FlowPRA was performed on pretransplant sera with no detectable PRA activity as assessed by CDC assays. FlowPRA antibody activity was then correlated with clinical outcome.Methods. PRA analysis by anti-human globulin enhanced (AHG) CDC and FlowPRA was performed on sera corresponding to final cross-match specimens from 219 cardiac allograft recipients. In addition, sera collected 3-6 months posttransplant from 91 patients were evaluated. The presence or absence of antibodies was correlated with episodes of rejection and patient survival, A rejection episode was considered to have occurred based on treatment with antirejection medication and/or histology,Results. By CDC, 12 patients (5.5%) had pretransplant PRA >10%. In contrast, 12 patients (32.9%) had pretransplant anti-HLA antibodies detectable by FlowPRA (34 patients with only class I antibodies; 7 patients with only class II antibodies; 31 patients with both class I and class II antibodies). A highly significant association (P
